Last $21.70 USD
Change Today -0.25 / -1.14%
Volume 788.0K
THRX On Other Exchanges
As of 8:10 PM 07/31/14 All times are local (Market data is delayed by at least 15 minutes).

theravance inc (THRX) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/20/13 - $34.52
52 Week Low
05/7/14 - $20.23
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for THERAVANCE INC (THRX)

theravance inc (THRX) Related Businessweek News

View More BusinessWeek News

theravance inc (THRX) Details

Theravance, Inc., a royalty management company, is focused on developing respiratory products. It receives royalty revenues RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI), ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI), and VI monotherapy through the Long-Acting Beta2 Agonist collaboration agreement with Glaxo Group Limited (GSK). The company is also entitled to a 15% interest in future payments made by GSK relating to the combination of UMEC/VI/FF and the Bifunctional Muscarinic Antagonist-Beta2 Agonist (MABA) program, as monotherapy, as well as in combination with other therapeutically active components, such as an inhaled corticosteroid, and other product or combination of products that might be discovered and developed under its LABA collaboration agreement with GSK. The company was formerly known as Advanced Medicine, Inc. and changed its name to Theravance, Inc. in April 2002. Theravance, Inc. was founded in 1996 and is headquartered in South San Francisco, California.

241 Employees
Last Reported Date: 03/3/14
Founded in 1996

theravance inc (THRX) Top Compensated Officers

Chairman, Chief Executive Officer, Member of ...
Total Annual Compensation: $986.9K
Co-Founder and Senior Vice President of Resea...
Total Annual Compensation: $485.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $515.4K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $466.7K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $457.4K
Compensation as of Fiscal Year 2013.

theravance inc (THRX) Key Developments

GlaxoSmithKline plc and Theravance, Inc. Announce Initiation of Phase III study with Fixed Dose Triple Combination Treatment FF/UMEC/VI in Patients with COPD

GlaxoSmithKline plc and Theravance Inc. announced the start of a global phase III study, known as IMPACT, to evaluate the efficacy and safety of the 'closed' triple combination of FF/UMEC/VI in patients with chronic obstructive pulmonary disease (COPD). IMPACT is the pivotal phase III study in a programme to evaluate a once-daily closed triple combination treatment of an inhaled corticosteroid (ICS); along-acting muscarinic antagonist (LAMA); and a long-acting beta2-adrenergic agonist (LABA) in patients with COPD. The IMPACT study will enrol approximately 10,000 patients and assess whether the combination of FF (fluticasone furoate, an ICS), UMEC (umeclidinium, a LAMA) and VI (vilanterol, a LABA), all delivered in GSK's Ellipta inhaler, can reduce the annual rate of moderate and severe exacerbations compared with two approved once daily COPD treatments, Relvar/Breo Ellipta (FF/VI), which is an ICS/LABA combination, and Anoro Ellipta (UMEC/VI), which is a LAMA/LABA combination.

GlaxoSmithKline plc and Theravance, Inc. Announce Anoro(R) Ellipta(R) (Umeclidinium/Vilanterol) Gains Approval in Japan for the Treatment of COPD

GlaxoSmithKline plc and Theravance Inc. announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Anoro(R) Ellipta(R) (umeclidinium/vilanterol) for the relief of various symptoms due to airway obstruction with chronic obstructive pulmonary diseases (chronic bronchitis, pulmonary emphysema) (in the case where concurrent use of long-acting inhaled muscarinic antagonist and long-acting inhaled beta agonist is required). Anoro is a once-daily combination treatment comprised of two bronchodilators, umeclidinium (UMEC), a long-acting muscarinic antagonist (LAMA), and vilanterol (VI), a long-acting beta agonist (LABA), in a single inhaler, the Ellipta. The approved dose in Japan is UMEC/VI 62.5/25mcg delivered once daily. Under the terms of the 2002 LABA collaboration agreement, Theravance is obligated to make a milestone payment of $10 million to GSK following MHLW approval of UMEC/VI in Japan. Following this approval, it is expected that launch will take place in Japan in the third quarter of 2014. The MHLW assessment of UMEC/VI involved a review of eight phase III clinical trials, evaluating approximately 6,000 COPD patients worldwide, including a specific 52 week, open-label, long-term safety study in Japanese patients.

Theravance, Inc. Appoints Theodore J. Witek, Jr. as Senior Vice President Corporate Partnerships, Clinical and Medical Affairs

Theravance Inc. announced the appointment of Theodore J. Witek, Jr. as Senior Vice President Corporate Partnerships, Clinical and Medical Affairs. Dr. Witek will report directly to Rick E Winningham, Chief Executive Officer and be responsible for working closely with Theravance's partners to achieve optimal results from the assets shared by the companies. In particular, Dr. Witek will be focused on the further development of the respiratory programs partnered with Glaxo Group Limited, including RELVAR /BREO ELLIPTA, ANORO ELLIPTA, the combination of umeclidinium/vilanterol/fluticasone furoate and the Bifunctional Muscarinic Antagonist-Beta(2) Agonist (MABA) monotherapy and combination programs. Dr. Witek brings over three decades of clinical and medical affairs experience to Theravance. Most recently, he served as President and Chief Executive Officer, Boehringer Ingelheim Canada Ltd.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
THRX:US $21.70 USD -0.25

THRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ironwood Pharmaceuticals Inc $14.80 USD -0.42
Nektar Therapeutics $10.55 USD -0.46
Progenics Pharmaceuticals Inc $4.78 USD -0.25
Sucampo Pharmaceuticals Inc $5.90 USD -0.26
Synergy Health PLC 1,359 GBp -2.00
View Industry Companies

Industry Analysis


Industry Average

Valuation THRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 673.8x
Price/Book 9.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 506.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact THERAVANCE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at